SAVER SCOREirAE Severity Risk Assessment
Model Context
The SAVER score integrates baseline clinical data (e.g., age, BMI, lab values) to predict the likelihood of Grade ≥ 3 immune-related adverse events during checkpoint inhibitor therapy.
Risk Profile
Clinical Strategy
Low risk for high-grade immune-related adverse events. Routine monitoring as per standard protocol.
Verified
Last Review: 2026
| Risk Category | Implication |
|---|---|
| Low Risk | Standard surveillance and patient education. |
| Intermediate Risk | Enhanced monitoring; consider more frequent lab checks (CBC, LFTs, Thyroid). |
| High Risk | High vigilance; early multidisciplinary involvement (e.g., GI, Pulm) at the first sign of any symptom. |
Modern Immuno-Oncology Consensus • Oncology Literature Review. 2025;Structured clinical decision support implementation.
Last Comprehensive Review: 2026
Clinical Context
We think this might be relevant to the clinical guidance for SAVER Score (Serious Adverse Event Risk).
Clinical Context
We think this might be relevant to the clinical guidance for SAVER Score (Serious Adverse Event Risk).
Clinical Context
We think this might be relevant to the clinical guidance for SAVER Score (Serious Adverse Event Risk).